The Experts below are selected from a list of 822 Experts worldwide ranked by ideXlab platform
Ann Reed Gaines - One of the best experts on this subject based on the ideXlab platform.
-
Disseminated Intravascular Coagulation Associated with Acute Hemoglobinemia or Hemoglobinuria Following Rho(D) Immune Globulin Intravenous Administration for Immune Thrombocytopenic Purpura.
Blood, 2005Co-Authors: Ann Reed GainesAbstract:Abstract The Food and Drug Administration (FDA) licensed Rho(D) immune globulin intravenous (anti-D IGIV) in March 1995 for treatment of immune thrombocytopenic purpura (ITP). The presumed mechanism of action of anti-D IGIV is extravascular hemolysis of anti-D-sensitized RBCs by splenic macrophages. Although seemingly inconsistent with this mechanism of action, acute Hemoglobinemia and hemoglobinuria have been reported and are listed in the professional package insert for anti-D IGIV as possible adverse events. Through November 30, 2004, FDA received 6 reports of disseminated intravascular coagulation (DIC) associated with “acute hemolysis” (or similar terms) following anti-D IGIV treatment for ITP (Gaines AR. Disseminated intravascular coagulation associated with acute Hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood.2005, 106(5):in press). All patients were clinically stable and were initially discharged home following anti-D IGIV administration. All were subsequently hospitalized for signs and symptoms of acute hemolysis or DIC. The mean decrease between pretreatment and nadir posttreatment hemoglobin levels was 5.8 g/dL (range: 3.0 to 9.6 g/dL); 4 patients received 2 to > 5 units of packed RBCs. Four patients whose baseline serum creatinine levels were within normal limits developed renal insufficiency; 2 of those patients underwent dialysis. The pediatric patient was subsequently discharged from the hospital without sequelae. However, all 5 adult patients remained hospitalized and died 3 to 10 days after anti-D IGIV administration. Attending or consulting physicians assessed that acute hemolysis and/or DIC caused or contributed to each death. Data from previously reported cases further suggested that previous uneventful administration of anti-D IGIV does not preclude the development of acute hemolysis upon subsequent administration of anti-D IGIV. These cases suggested that patients treated with anti-D IGIV for ITP who experience acute Hemoglobinemia or hemoglobinuria be monitored for the development of DIC. To increase our knowledge about the seemingly rare but potentially serious complication of DIC following anti-D IGIV treatment for ITP, physicians and other health care professionals are encouraged to submit serious adverse event reports to the anti-D IGIV manufacturer or to FDA. Contact information for reporting adverse events to the manufacturer of any FDA-approved product is generally available in the professional package insert or on manufacturer- or distributor-sponsored web sites. Alternatively, adverse events can be reported directly to FDA through its adverse event reporting system, MedWatch, by Internet at http://www.fda.gov/medwatch, by telephone at 1-800-FDA-1088; by fax at 1-800-FDA-0178; or by mail at MedWatch, HF-2, 5600 Fishers Lane, Rockville, MD 20852-9787.
-
disseminated intravascular coagulation associated with acute Hemoglobinemia or hemoglobinuria following rho d immune globulin intravenous administration for immune thrombocytopenic purpura
Blood, 2005Co-Authors: Ann Reed GainesAbstract:The Food and Drug Administration (FDA) licensed Rho(D) immune globulin intravenous (anti-D IGIV) on March 24, 1995, for treatment of immune thrombocytopenic purpura (ITP). A previous review described data on 15 patients who experienced acute Hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP or secondary thrombocytopenia. Eleven of those patients also experienced clinically compromising anemia, transfusion with packed red blood cells, renal insufficiency, dialysis, or death. That review suggested that patients receiving anti-D IGIV be monitored for those and other potential complications of Hemoglobinemia, particularly disseminated intravascular coagulation (DIC). Through November 30, 2004, the FDA received 6 reports of DIC associated with “acute hemolysis” (or similar terms), 5 of which involved fatalities. The attending or consulting physicians assessed that acute hemolysis or DIC caused or contributed to each death. This review presents the first case series of DIC associated with acute Hemoglobinemia or hemoglobinuria following anti-D IGIV administration for ITP. The purpose of this review is to increase awareness among physicians and other health care professionals that DIC may be a rare but potentially severe complication of anti-D IGIV treatment. Increased awareness of DIC as a diagnostic possibility may enable prompt recognition and medical intervention in affected patients.
-
Acute onset Hemoglobinemia and/or hemoglobinuria and sequelae following Rho(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients
Blood, 2000Co-Authors: Ann Reed GainesAbstract:Rho(D) immune globulin intravenous (anti-D IGIV) was licensed by the United States Food and Drug Administration (FDA) in March 1995 to treat patients with immune thrombocytopenic purpura (ITP). Anti-D IGIV induces extravascular hemolysis, an expected adverse reaction that is consistent with the presumed mechanism of action. Between licensure and April 1999, the FDA received 15 reports of Hemoglobinemia and/or hemoglobinuria following anti-D IGIV administration that met the case definition for this review. The mechanism responsible for Hemoglobinemia and/or hemoglobinuria is unexplained. Review of these reports was prompted by the seriousness and the unexpectedness of treatment-associated sequelae experienced by 11 patients. Of these patients, 7 developed sufficient onset or exacerbation of anemia that orders were written for packed red blood cell transfusions, although only 6 patients were transfused. Eight patients experienced the onset or exacerbation of renal insufficiency, and 2 patients underwent dialysis. One patient died due to complications of exacerbated anemia. Six patients experienced 2 to 3 sequelae. Absent validated incidence data, a 1.5% estimated incidence rate from published clinical trial data and a 0.1% estimated reporting rate from FDA and drug utilization data were calculated for reported cases of Hemoglobinemia and/or hemoglobinuria. This review presents the first case series of anti-D-IGIV–associated Hemoglobinemia and/or hemoglobinuria and provides pretreatment and posttreatment clinical and laboratory findings of the case series patients. The primary purpose of this review is to increase awareness of this potentially serious occurrence among physicians and health care professionals who manage ITP patients treated with anti-D IGIV, thereby enabling prompt recognition and treatment of sequelae.
-
acute onset Hemoglobinemia and or hemoglobinuria and sequelae following rho d immune globulin intravenous administration in immune thrombocytopenic purpura patients
Blood, 2000Co-Authors: Ann Reed GainesAbstract:Rho(D) immune globulin intravenous (anti-D IGIV) was licensed by the United States Food and Drug Administration (FDA) in March 1995 to treat patients with immune thrombocytopenic purpura (ITP). Anti-D IGIV induces extravascular hemolysis, an expected adverse reaction that is consistent with the presumed mechanism of action. Between licensure and April 1999, the FDA received 15 reports of Hemoglobinemia and/or hemoglobinuria following anti-D IGIV administration that met the case definition for this review. The mechanism responsible for Hemoglobinemia and/or hemoglobinuria is unexplained. Review of these reports was prompted by the seriousness and the unexpectedness of treatment-associated sequelae experienced by 11 patients. Of these patients, 7 developed sufficient onset or exacerbation of anemia that orders were written for packed red blood cell transfusions, although only 6 patients were transfused. Eight patients experienced the onset or exacerbation of renal insufficiency, and 2 patients underwent dialysis. One patient died due to complications of exacerbated anemia. Six patients experienced 2 to 3 sequelae. Absent validated incidence data, a 1.5% estimated incidence rate from published clinical trial data and a 0.1% estimated reporting rate from FDA and drug utilization data were calculated for reported cases of Hemoglobinemia and/or hemoglobinuria. This review presents the first case series of anti-D-IGIV–associated Hemoglobinemia and/or hemoglobinuria and provides pretreatment and posttreatment clinical and laboratory findings of the case series patients. The primary purpose of this review is to increase awareness of this potentially serious occurrence among physicians and health care professionals who manage ITP patients treated with anti-D IGIV, thereby enabling prompt recognition and treatment of sequelae.
-
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Disseminated
1995Co-Authors: Ann Reed GainesAbstract:intravascular coagulation associated with acute Hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpur
Akira Kamitamari - One of the best experts on this subject based on the ideXlab platform.
-
Unstable Hemoglobinemia, Hb Buenos Aires, Bryn Mawr, Followed Up for Eighteen Years
2016Co-Authors: Chie Ande, Kosei Moriyama, Yoshiyuki Nakashima, Akira Ohmiya, Hirofumi Yoshikuni, Hiroyuki Moriuchi, Yoshiro Tsuji, Yuzo Ohba, Yukio Hattori, Akira KamitamariAbstract:Abstract A 20-year-old man has been under observation for 18 years because of unstable Hemoglobinemia, Hb Buenos Aires, Bryn Mawr (fl-globin, Phe85Ser). At the age of 19 years, he was hospitalized because of fever and hemolytic crisis, and the symptoms resolved after infusion of antibiotics. Nucleotide sequencing of the fl-globin gene confirmed that the patient was heterozygous for the mutation. The patient's erythrocytes showed an increased affinity for oxygen and a prolonged glycerol lysis time. We review a previously reported single family and 5 other cases, and discuss the clinical significance of splenectomy and plasma-derived haptoglobin
-
Unstable Hemoglobinemia, Hb Buenos Aires, Bryn Mawr, followed up for eighteen years.
Fukuoka igaku zasshi = Hukuoka acta medica, 2004Co-Authors: Chie Ando, Kosei Moriyama, Yoshiyuki Nakashima, Akira Ohmiya, Hirofumi Yoshikuni, Hiroyuki Moriuchi, Yoshiro Tsuji, Yuzo Ohba, Yukio Hattori, Akira KamitamariAbstract:A 20-year-old man has been under observation for 18 years because of unstable Hemoglobinemia, Hb Buenos Aires, Bryn Mawr (beta-globin, Phe85Ser). At the age of 19 years, he was hospitalized because of fever and hemolytic crisis, and the symptoms resolved after infusion of antibiotics. Nucleotide sequencing of the beta-globin gene confirmed that the patient was heterozygous for the mutation. The patient's erythrocytes showed an increased affinity for oxygen and a prolonged glycerol lysis time. We review a previously reported single family and 5 other cases, and discuss the clinical significance of splenectomy and plasma-derived haptoglobin.
Robert M. Rosa - One of the best experts on this subject based on the ideXlab platform.
-
Renal Disorders in Sickle Hemoglobinemia
Therapy of Renal Diseases and Related Disorders, 1991Co-Authors: Stephanie Lear, Robert M. RosaAbstract:Sickle Hemoglobinemia, a term that refers to the presence of sickle hemoglobin (Hb-S) in either the heterozygous or homozygous form, has been associated with numerous and widely varying forms of disordered renal function, the majority of which are ultimately a consequence of the sickling process. In the presence of hypoxia, acidosis, or hyperosmolality (which causes red cells to shrink, thereby increasing the intracellular hemoglobin concentration), the rate of gelation and tactoid formation increases and red cells become sickled (1–5). When this morphologic change occurs in the capillary bed there is an increase in blood viscosity. Resistance to blood flow is thereby increased, passage of red cells through capillaries is further delayed, and more deoxygenation and sickling ensue. This process, which has been described as “a vicious cycle of erythrostasis” (6), can eventuallv lead to ischemia and infarction of tissue.
Robinson-ortiz Angélica - One of the best experts on this subject based on the ideXlab platform.
-
Valores de referencia de Hemoglobinemia en población Colombiana de 1 a 18 años por género y altitud
Facultad de medicina, 2017Co-Authors: González-patiño Angélica, Robinson-ortiz AngélicaAbstract:Introducción: \ud La concentración de hemoglobina total es uno de los indicadores más comúnmente medidos en sangre. Sin embargo, sus valores varían de acuerdo con la altitud, sexo y edad, entre otros, por lo cual es necesario contar con valores de referencia ajustados para estas condiciones con el fin de establecer adecuadamente el diagnóstico tanto de anemia como eritrocitosis. El objetivo de este estudio fue establecer los valores de referencia para Hemoglobinemia en la población colombiana entre 1 y 18 años, de acuerdo con la edad, sexo y altitud del lugar de residencia. \ud \ud Materiales y métodos: A partir de la encuesta nacional de salud (ENDS) y de situación nutricional (ENSIN) Colombia 2010, se analizaron los valores de Hemoglobinemia provenientes de los individuos de 1 a 18 años, tras haber excluido a los sujetos con condiciones inflamatorias (proteína C reactiva >1,2 mg/ml) y con depleción de las reservas de hierro (ferritina sérica 1.2 mg/dl) and with depleted iron stores (serum ferritin
Angelica Robinsonortiz - One of the best experts on this subject based on the ideXlab platform.
-
valores de referencia de Hemoglobinemia en poblacion colombiana de 1 a 18 anos por genero y altitud
instname:Universidad del Rosario, 2015Co-Authors: Angelica Gonzalezpatino, Angelica RobinsonortizAbstract:Introduccion: La concentracion de hemoglobina total es uno de los indicadores mas comunmente medidos en sangre. Sin embargo, sus valores varian de acuerdo con la altitud, sexo y edad, entre otros, por lo cual es necesario contar con valores de referencia ajustados para estas condiciones con el fin de establecer adecuadamente el diagnostico tanto de anemia como eritrocitosis. El objetivo de este estudio fue establecer los valores de referencia para Hemoglobinemia en la poblacion colombiana entre 1 y 18 anos, de acuerdo con la edad, sexo y altitud del lugar de residencia. Materiales y metodos: A partir de la encuesta nacional de salud (ENDS) y de situacion nutricional (ENSIN) Colombia 2010, se analizaron los valores de Hemoglobinemia provenientes de los individuos de 1 a 18 anos, tras haber excluido a los sujetos con condiciones inflamatorias (proteina C reactiva >1,2 mg/ml) y con deplecion de las reservas de hierro (ferritina serica <22 μg/l), de acuerdo con la edad, sexo y altitud del lugar de residencia, utilizando el paquete estadistico IBM SPSS Statistics 21.0. Resultados y discusion: En la poblacion seleccionada se encontro una prevalencia de anemia ferropenica entre 0% y 50%; una prevalencia de anemia no ferropenica de 0% a 18,8%. Se observaron incrementos significativos en la Hemoglobinemia de acuerdo con edad, sexo y altitud a partir de 500 msnm, y para estos ultimos los valores encontrados fueron superiores a los establecidos por la Organizacion Mundial de Salud. Tambien se encontraron diferencias significativas en la Hemoglobinemia de acuerdo con la etnia.